Moderna, Inc. (NASDAQ:MRNA) Position Cut by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 59.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 115,932 shares of the company’s stock after selling 168,512 shares during the quarter. Victory Capital Management Inc.’s holdings in Moderna were worth $4,820,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp boosted its stake in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its position in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the period. Wellington Management Group LLP increased its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of MRNA stock opened at $34.62 on Friday. The stock has a market cap of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. The stock has a 50-day moving average of $35.94 and a 200-day moving average of $47.37. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Analyst Ratings Changes

MRNA has been the topic of several recent research reports. Bank of America cut their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Citigroup began coverage on shares of Moderna in a research report on Thursday. They issued a “neutral” rating and a $40.00 price target for the company. Finally, UBS Group reduced their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $59.60.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.